CdnP (Mycobacterium tuberculosis strain ATCC 25618/H37Rv recombinant)

Proteins - Enzymes

Zoom

Cat No: 22809

Proteins - Enzymes

Cyclic di-nucleotide phosphodiesterase (CdnP, also known as Rv2837c) is a soluble, stand-alone phosphodiesterase in regulating cyclic dinucleotide signaling during intracellular infections of M. tuberculosis.{36095} Studies have found that CdnP is cap...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

ATCC25618 H-37Rv H37-Rv DHHA-1 IFN? Escherichia

Product Overview:
Cyclic di-nucleotide phosphodiesterase (CdnP, also known as Rv2837c) is a soluble, stand-alone phosphodiesterase in regulating cyclic dinucleotide signaling during intracellular infections of M. tuberculosis.{36095} Studies have found that CdnP is capable of hydrolyzing cyclic di-adenosine monophosphate (c-di-AMP; Item No. 17753) into two AMPs as a strategy to avoid activation of the innate immune response of the host. M. tuberculosis infection leads to cytosolic release of c-di-AMP, which is recognized by stimulator of interferon genes (STING) and subsequently triggers type I interferon response.{36096} Other studies have shown that deletion or inhibition of CdnP attenuates the M. tuberculosis virulence both in vitro and in vivo.{36097,33472}

Size	100 µg
Shipping	dry ice
Formulation	50 mM HEPES, pH 8.0, with 150 mM sodium chloride
Purity	≥70% estimated by SDS-PAGE
Custom Code	3504.00
UNSPSC code	12352204

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : CdnP (<em>Mycobacterium tuberculosis</em> strain ATCC 25618/H37Rv recombinant) There are 7 products.